To position istaroxime for Phase 3 readiness, WINT launched the small Phase 2 study in SCAI Stage C. SCAI Stage C cardiogenic shock is a more severely ill patient population than the participants ...
The SHOCK study (SHould we emergently revascularize ... Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of ...
Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial Receive the the latest news, research, and presentations from major ...
Zacks Small Cap Research on MSN10d
WINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation – Initiating CoverageWINT READ THE FULL WINT RESEARCH REPORT Multiple Programs Focus on Unmet Needs In Cardiogenic Shock & AHF Pennsylvania-based Windtree Therapeutics, Inc. (NASDAQ:WINT) is a biopharmaceutical company ...
The American College of Cardiology and the American Heart Association today released an updated clinical practice guideline for managing individuals experiencing acute coronary syndrome (ACS). The ...
More information: Matthew Sherwood et al, SCAI Expert Consensus Statement on Alternative Access for Transcatheter Aortic Valve Replacement, Journal of the Society for Cardiovascular Angiography ...
To position istaroxime for Phase 3 readiness, WINT is also enrolling a small Phase 2 study in SCAI Stage C, administering istaroxime to patients with the more severe form of cardiac shock ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback